Incyte Pharma Drug Shows Positive Effect in Treatment of a Certain Type of Blood Cancer
December 9, 2025
Source: drugdu
34
Incyte Pharma states new clinical data shows its monoclonal antibody drug INCA033989 can rapidly and significantly reduce spleen volume, alleviate associated symptoms, and improve anemia in patients with myelofibrosis who have a specific genetic mutation. The preliminary research results come from treating patients with CALR mutation (mutCALR) myelofibrosis with the drug as monotherapy and in combination with ruxolitinib. The drug demonstrated good safety, with no dose-limiting toxicities reported. Incyte Pharma plans to initiate a registration program for myelofibrosis treatment in 2026.
https://finance.eastmoney.com/a/202512073584646874.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- How to Use B2B Platforms to Expand Global Sales Channels December 10, 2025
- WHO releases guidelines for the use of new weight-loss drugs December 9, 2025
- Grand Pharmaceutical’s Class 1 innovative traditional Chinese medicine drug GPN01360 has reached its clinical endpoint in the Phase II clinical trial in China December 9, 2025
- Ophthalmic preparation GB10 injection receives clinical trial approval notice December 9, 2025
- Huadong Medicine enters commercialization partnership with Sinorda Pharma December 9, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
